Sources: Cures Could Move Soon; New REMS Bill Eyed As Pay-For

Lawmakers aim to move on a compromise 21st Century Cures package the first week of the lame-duck session, a congressional source told Inside Health Policy . Talks are continuing on a pharma-friendly version of a Risk Evaluation and Mitigation Strategies (REMS) measure that could be used as a pay-for, congressional sources said. Critics of the emerging REMS measure slam it as too kind to brand-name drug makers, and point fingers at the Pharmaceutical Research and Manufacturers of America as having...